ReNeuron Group plc Analyst Conference Call
January 06 2021 - 2:00AM
RNS Non-Regulatory
TIDMRENE
ReNeuron Group plc
06 January 2021
6 January 2021 AIM: RENE.L
RNS REACH
ReNeuron Group plc
("ReNeuron" or the "Company")
Analyst Conference Call
ReNeuron Group plc (AIM: RENE.L), a UK-based global leader in
the development of cell-based therapeutics, will host a conference
call for analysts at 10.00am GMT today to discuss the Company's
recent half year results, fundraising and outlook for the year
ahead.
Analysts who require dial-in details, please contact Buchanan at
reneuron@buchanan.uk.com.
A recorded webcast of the analyst conference call, including
investor presentation slides, will be made available during the
afternoon of 6 January 2021 at this link:
https://webcasting.buchanan.uk.com/broadcast/5fd23c59ca22cd76f9d3c662
The recorded webcast will also be made available at the investor
centre of ReNeuron's website,
http://www.reneuron.com/investors/investor-centre/ .
ENQUIRIES:
ReNeuron +44 (0) 20 3819 8400
Olav Hellebø, Chief Executive Officer
Michael Hunt, Chief Financial Officer
Buchanan (UK Media/Investor relations) +44 (0) 20 7466 5000
Mark Court, Sophie Wills, Tilly Abraham
Stifel Nicolaus Europe Limited (NOMAD and Joint Broker)
Ben Maddison, Stewart Wallace +44 (0) 20 7710 7600
N+1 Singer (Joint Broker)
Aubrey Powell, James Moat, Hannah Woodley +44 (0) 20 7496 3000
About ReNeuron
ReNeuron is a global leader in cell-based therapeutics,
harnessing its unique stem cell technologies to develop 'off the
shelf' stem cell treatments, without the need for immunosuppressive
drugs. The Company's lead cell therapy candidate is in clinical
development for the blindness-causing disease, retinitis
pigmentosa.
ReNeuron is also advancing its proprietary exosome technology
platform as a potential delivery system for drugs that treat
diseases of the brain. The Company also has the ability through its
conditionally immortalised induced pluripotent stem cell (iPSC)
platform to make any tissue cells of choice; in-house programmes
are focused on treatments for blood cancers and diabetes.
ReNeuron's shares are traded on the London AIM market under the
symbol RENE.L. For further information visit www.reneuron.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAUVRWRARUARAR
(END) Dow Jones Newswires
January 06, 2021 02:00 ET (07:00 GMT)
Reneuron (LSE:RENE)
Historical Stock Chart
From Apr 2024 to May 2024
Reneuron (LSE:RENE)
Historical Stock Chart
From May 2023 to May 2024